The number of malignancies where immunotherapy has gained approval has rapidly grown, and increasingly, immunotherapy is being combined with other treatment modalities. This advancement of science and development of new immunotherapeutic agents requires a multidisciplinary approach.
Registration
Please register below or via email.
Mail
c3z@usz.ch